Dynavax Technologies

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company launched HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], its first commercial product, in February 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, martial and veteran status.